This document discusses gastric proton pump inhibitors (PPIs), which are irreversible inhibitors of the gastric parietal cell proton pump that reduce acid production in the stomach. It details four specific PPIs: omeprazole, lansoprazole, rabeprazole, and pantoprazole, describing their chemical properties, mechanisms of action, and therapeutic uses for conditions like GERD and peptic ulcer disease. The document emphasizes their importance in treating acid-related disorders and preventing complications such as esophageal cancer.